Biopharma's Flexible Imperative. Robert Dream Principal, HDR COMPANY LLC April 24, 2013
|
|
- Melvin Clark
- 5 years ago
- Views:
Transcription
1 Biopharma's Flexible Imperative Robert Dream Principal, HDR COMPANY LLC April 24, 2013
2 Biopharma's Flexible Imperative Introduction Can history help us see the future Comparing 1918 and today Pandemic influenza as an example Public health and healthcare delivery Current preparedness challenges Where do we go from here Case Studies 2
3 The Backdrop Recently, a number of different trends have converged to demand a new type of biopharmaceutical delivery facility one that emphasizes flexibility and agility. 3
4 An Overview Drawing this new blueprint are: Business needs to minimize timelines and financial risks Biotech on Demand, and the ability to shore up local manufacturing capacity, quickly, to meet market needs National security needs for systems that can easily and rapidly respond to biological attacks Urgent national health needs to protect the public from large-scale, fast moving epidemics and pandemics 4
5 Understanding Pandemic Pandemic An epidemic that becomes very widespread and affects a whole region, a continent or the Globe. Influenza pandemics; o 10 pandemics recorded in the last 300 years o 10 to 49 years between pandemics (50,000, ,000,000 deaths worldwide)
6 1918 Source: Center for Infectious Disease Research and Policy 6
7 16 different Hemagglutinin antigens (HA) 9 different Neuraminidase antigens (NA) HANA, e.g.: : H1N1, Spanish Flu : H2N2, Asian Flu : H3N2, Hong Kong Flu 7
8 Antigenic shift and drift (Virology, Epidemiology) Influenza virus undergoes two kinds of changes. Drift: One is a series of mutations that occurs over time and causes a gradual evolution of the virus. This is called antigenic drift Shift: The other kind of change is an abrupt change in the hemagglutinin and/or the neuraminidase proteins. This is called antigenic shift In this case, a new subtype of the virus suddenly emerges. Influenza type A virus undergoes both kinds of changes and could cause a pandemics Influenza type B virus changes by the more gradual process of antigenic drift only and does not cause any pandemics Influenza type C is less common than types A & B and usually only causes mild disease in children 8
9 Facilities of the Future, Today : issues and technologies driving new Biopharmaceutical manufacturing facility design and construction, both in the US, EU, and in growing markets. Among the questions; US/EU: Where are the facilities being built and how will that affect industry employment trends, and drug supply to the patients? How are they being designed? In newer markets: the issues are many, including: Imperfect harmonization among FDA, SFDA, EU, Japan, and WHO. What should companies expect and how can they prepare? How should they plan to handle data, to ensure IP security (e.g.: INDIA patent nullification will it spread)? Energy conservation in design Layout and systems: how to facilitate collaboration when the culture emphasizes the opposite How to work with local and global suppliers?
10 Do a risk assessment and analyze - Why we need a facility - Why it has to be: Modular, Flexible, and/or Rigid Cost, capital investment Time to market Preclinical and/or Clinical operation that goes through multiple product changes in a very short time We don t know what we are planning to manufacture it is pandemic response facility Regions of the world where crafts is not available to build a regulatory compliant and safe clean room The life of the product is very short and change over requires flexibility within a short time And so on
11 How to build and sustain a quality culture so your organization can: Improve process Minimize risk Decrease cost Increase productivity Remain compliant
12 Agency: Department of Health and Human Services (DHHS) Biomedical Advanced Research and Development Authority (BARDA) Agency: Department of Defense (DoD) Defense Advanced Research Projects Agency (DARPA) 12
13 The BARDA Strategic Plan emphasizes five goals for BARDA will use to accomplish its mission: An advanced development pipeline replete with medical countermeasures and platforms to address unmet public health needs, emphasizing innovation, flexibility, multi-purpose and broad spectrum application, and long-term sustainability. A capability base to provide enabling core services to medical countermeasure innovators. Agile, robust and sustainable U.S. manufacturing infrastructure capable of rapidly producing vaccines and other biologics against pandemic influenza and other emerging threats Responsive and nimble programs and capabilities to address novel and emerging threats A ready capability to develop, manufacture and facilitate distribution of medical countermeasures during public health emergencies 13
14 Flexible, multi-product, multi-technology capability within a biomanufacturing ecosystem; commercial operator(s) Flexible multi-product, multi-technology pilot plant with robust process development capabilities & commercial / SNS (Strategic National Stockpile) facility Commercial / SNS Facility 8-10 modular process trains for surge of pandemic flu and/or ongoing MCM production for SNS Full surge capability to 10X baseline within 24 hours Stockpile pods with complete processes for major biothreats Life cycle management program with scheduled rotation through production Consideration of adjacent facility for integration/validation of clinic-ready emerging technology platforms (DARPA AMP and others) Highly integrated intermediate development cluster Animal model development and validation, biomarker evaluation, imaging, GLP pre-clinical studies and animal rule efficacy, and human Phase 1 clinical trials. 14
15 Operational Goal From pathogen emergence to millions of doses of definitive therapy in 16 weeks Deployed as Strategic and Tactical Assets Transitioned to DTRA and JPEO- CBD for Advanced Development Mimic System Transitioning AMP: Accelerated Manufacture of Pharmaceuticals Program AMP Ongoing DTRA: Defense Threat Reduction Agency JPEO-CBD: Joint Program Executive Office for Chemical and Biological Defense 15
16 Case Studies (Two): Flexible Manufacturing Viral Vector by Mammalian Cell Culture Vaccines (Influenza) Monoclonal Antibody (mab) Sub-Unit Protein Vaccines Autologous Cancer Vaccines Virus Vector Manufacturing by Plant Culture 16
17 National Center for Therapeutics Manufacturing 17
18 Scope Flexible-by-design architecture and platforms Accommodates multiple production technology platforms and products: allows utilization of best of breed flexible bioprocess technologies Completely reconfigurable clean rooms required for campaigns and surge, without interruption of ongoing operations. Personalized therapeutics to moderate scale bioreactors (2000 L) Focus on Phase I, Phase II, and Phase III run in Shared core services; medium throughput fill and finish Educational programs to train U.S. workforce in commercial cgmp-compliant production and related R&D 18
19 Operating Platform Modular, scalable, mobile clean rooms rated at ISO 8, 7 & 5 Operational design (42 Long x 18 Wide x 13 High) and can accommodate up to 2000 liter bioreactor Dual redundant systems including 2 AHUs, SCADA, bag in / bag out HEPA filtration for supply and exhaust Remote quality control, security, and maintenance via wireless communications PODs will allow significant increase in the tooth-to-tail ratio for bio-manufacturing facilities Predicted reduction in operational costs and energy utilization of at least 50%. 19
20 Therapeutics Manufacturing Facility Academic Wing: ~48,000 ft 2 GMP Bioprocess Wing: ~104,000 ft 2 20
21 Manufacturing Space 21
22 Single Use Technologies 22
23 MBF Interior Standard: 42 Long x 18 Wide x 13 High 23
24 Exterior Utility Connection 24
25 HVAC System - Supply & Exhaust 25
26 Non-Viral Manufacturing Pressure Scheme MBF Mechanical Space MBF Mechanical Space P~+36 Pascal's P~+24 Pascal's + 0 Ambient P~12 Pascal's - P~-12 Pascal's ISO 7 Space ISO 8 Space Material Pass Through Processing Suite Gray Space Service Corridor Processing Suite Gowning De-Gowning Gowning Clean - + Corridor Gray Space + + Material Pass Through De-Gowning 26
27 Viral Manufacturing Pressure Scheme MBF Mechanical Space MBF Mechanical Space P~-36 Pascal's P~-24 Pascal's - 0 Ambient + ++ P~-12 Pascal's P~+12 Pascal's P~+24 Pascal's ISO 7 Space ISO 8 Space Material Airlock Processing Suite Gray Space Clean Corridor Service Corridor Processing Suite Gowning Gowning De-Gowning Gray Space + + Material Airlock De-Gowning 27
28 Personnel Flow MBF Specific Controlled Personnel Flows for USP With Limited DSP Access MBF Mechanical Space MBF Mechanical Space Processing Suite USP Processing Suite DSP ISO 7 Space ISO 8 Space Material Pass Through Gowning Material Pass Through De-Gowning Gowning De-Gowning Clean Corridor Service Corridor 28
29 Material Flow MBF Mechanical Space MBF Mechanical Space Processing Suite Processing Suite ISO 7 Space ISO 8 Space Material Pass Through Gowning Material Pass Through De-Gowning Gowning De-Gowning Clean Corridor Service Corridor 29
30 Waste Flow MBF Mechanical Space MBF Mechanical Space Solid Waste & Small Volume Liquid Carboy Pass Through & Transport Enclosure Cart Processing Suite Processing Suite ISO 7 Space ISO 8 Space Material Airlock Gowning Material Airlock De-Gowning Gowning De-Gowning Clean Corridor Service Corridor 30
31 Isolator Technology small and flexible Production lines tend to become smaller and more flexible multiple product lines require short change over times down time has to be reduced Short decontamination cycles Short cleaning and filter change over time Short glove testing time Modular isolator system
32 Short Glove Testing Time Wireless Glove Tester
33 Short Cleaning and Filter Change over Time Filter cartridge
34 Short Decontamination Cycles H2O2 Decontamination isolator carrier gas nozzle H 2 O 2 vapor closed vaporizer H 2 O 2 solution
35 Short Decontamination Cycles Cycle Time to <1ppm 2 hours down to 0,5ppm Genentech
36 Short Decontamination Cycles Cycle Time to <100ppb 0,1ppm 5 hours
37 Manufacturing Profile 1. A Modular Bioprocessing Unit (MBU), is a portable, self contained environment that allows for drug development in multiple locations. The key to the design of these MBUs is that they are self-contained with inherent air handling and other critical equipment and controls components. 2. Each MBU is used for a single, biologically distinct technology (bacteria, mammalian cells, plants, etc.), thereby eliminating any cross contamination issues with regulatory agencies. 3. When MBUs are not in use, they are moved to cleaning/refurbishing areas and ready MBUs are plugged in for manufacturing. 37
38 A Unit Being Moved in a Manufacturing POD 38
39 Necessary Connections Being Made 39
40 Single Use Reactor and Support Equipment/Controls 40
41
42 Case Study: GreenVAX Plant Based Vaccine Manufacturing 42
43 Project Objective and Metrics Objective: Perform the R&D required to deliver recombinant H1N1 subunit vaccine, expressed in hydroponic tobacco plants, at a scale of one kilogram of purified vaccine protein per month, that meets all regulatory requirements for purity, quality, and current cgmp Total project timeline: 12 months from initial funding to first 10 million dose test run Technology Investment Agreement (TIA) between DARPA & Texas Plant-Expressed Vaccine Consortium Consortium contribution: $21,144,223 Federal contribution: $39,998,063 Facility expandable to 100MM doses per month; or dual product capabilities, for ~$18M additional 43
44 Plant Based Vaccine Manufacturing Timeline Tobacco based vaccine system (Fraunhofer) optimized through DARPA AMP Program Yield of H1N1 recombinant protein now mg/kg of plant biomass at pilot scale facility in Delaware Preliminary subunit vaccine highly protective in ferret challenge model Clinical development plan for Phase 1 under DARPA management GreenVax Consortia will continue clinical development upon completion of current DARPA project 44
45 Plant Under Construction Precast Tilt-up Concrete Panels Double-T Roof Panels 45
46 Plant Based Vaccine Manufacturing 46
47
48 Pre and Post Infiltration Racks Post Infiltration Pre Infiltration 48
49 Infiltrator 49
50 Overall Schedule D e c 0 9 F e b 1 0 J u n e 1 0 S e p t 1 0 D e c 1 0 Proposal submitted Contract Signed Program Kickoff Engineering and Process Design and Specification Process Control Design Installation of Process Equipment Production of 1kg Purified Antigen 50
51 A platform that has been successfully used for the development and manufacture of a wide range of vaccines and therapeutics: Low-cost, rapid production of proteins Correctly folded and biologically active cgmp-qualified master virus banks and cell line Extensive clinical use and regulatory history Scalable to large volumes and high cell densities FDA-qualified cell line and virus bank cgmp clinical materials at an affordable price Manufacturing and treatment facilities on a moment notice 51
52 Biopharma s Flexible Imperative Q&A Robert F Dream HDR COMPANY LLC Robert.f.dream@gmail.com (513) (513)
Application of Single-Use Technologies in Medical Countermeasure Development & Manufacturing for Emerging Pathogens
Application of Single-Use Technologies in Medical Countermeasure Development & Manufacturing for Emerging Pathogens BPSA s 7 th Annual Int l Single-Use Summit July 13, 2017 Mike Angelastro Director (acting),
More informationOPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES
OPPORTUNITIES FOR HHS & DOD COLLABORATION FOR MEDICAL COUNTERMEASURES Dr. Robert P. Kadlec Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services 2017 Chemical and
More informationU.S. Readiness for Pandemics
0 U.S. Readiness for Pandemics 5 th National Emergency Management Summit Brooklyn, NY September 15, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary for Preparedness & Response (HHS/ASPR) Director
More informationPROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE
PROMOTING AN EFFECTIVE MEDICAL COUNTERMEASURES ENTERPRISE Gerald R. Kovacs, PhD Director, Division of Chem/Bio/Rad/Nuc Medical Countermeasures Biomedical Advanced Research and Development Authority Assistant
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationAn Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines
More informationDRAFT WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE WGE GETREADYNOWGE GETREADYNOWGE GETREADYNOWGE GETREADYNOWGE.
What Can I Do As A National Leader? This publication was produced by the AI.COMM project, managed by the Academy for Educational Development (AED), and funded by the U.S. Agency for International Development
More informationMichel BAIJOT Vice President, WW Business Development & Strategic Alliances
Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business
More informationPage 1 of 5 For Immediate Release Office of the Press Secretary July 17, 2007 Fact Sheet: Implementation of the National Strategy for Pandemic Influenza A One-Year Summary Of Efforts To Better Protect
More informationInfluenza: The Threat of a Pandemic
April, 2009 Definitions Epidemic: An increase in disease above what you what would normally expect. Pandemic: A worldwide epidemic 2 What is Influenza? Also called Flu, it is a contagious respiratory illness
More informationStainless-steel vs Single-use: The Vaccines Perspective
Stainless-steel vs Single-use: The Vaccines Perspective CMO-Biomanufacturer Panel Tue 21 April, Noon-1:30pm, Exhibit Hall Daniel C.Vellom, PhD Sr. Director Global Technology Innovation 2015 INTERPHEX 1
More informationEC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
More informationUniversity of Colorado Denver. Pandemic Preparedness and Response Plan. April 30, 2009
University of Colorado Denver Pandemic Preparedness and Response Plan April 30, 2009 UCD Pandemic Preparedness and Response Plan Executive Summary The World Health Organization (WHO) and the Centers for
More informationFinancing Influenza Vaccine R&D
Financing Influenza Vaccine R&D WHO GAP-II Geneve, Switzerland July 13, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary & Director HHS/ASPR/BARDA 0 Vaccine Development is Risky, Lengthy, & Expensive
More informationTESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO)
TESTIMONY OF PHYLLIS ARTHUR, SENIOR DIRECTOR FOR VACCINES, IMMUNOTHERAPEUTICS AND DIAGNOSTICS POLICY, BIOTECHNOLOGY INDUSTRY ORGANIZATION (BIO) SENATE HELP COMMITTEE May 17, 2011 Good morning Chairman
More informationApproaches to Pandemic Influenza Vaccine Preparedness
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Approaches to Pandemic Influenza Vaccine Preparedness Julie Schafer, MPH, MS Influenza
More informationChallenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats
Challenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats Susan Dana Jones, Ph.D. BioProcess Technology Consultants, Inc. BIO 2009 Process Zone Theater Atlanta, GE May 20, 2009
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationStockpiling of H5N1 vaccines
Stockpiling of H5N1 vaccines Norbert W. Hehme EVM Influenza Pandemic Working Group EU-Commission Workshop on Stockpiling of Medicinal Products February 21/22, 2008 European Vaccine Manufacturers 1 (EVM)
More informationPublic Health Emergencies: Mass Dispensing in the Community
Public Health Emergencies: Mass Dispensing in the Community Chrissy Gamboa - Pinal County Public Health Chris Lyons, RN - Maricopa County Public Health Role of Public Health in an Disease prevention Emergency
More informationTrends and Challenges in Technical and Manufacturing Collaboration. Alex Neverov Vaccine World MENA & CIS NOV 2014
Trends and Challenges in Technical and Manufacturing Collaboration Alex Neverov Vaccine World MENA & CIS 2014 20 NOV 2014 Topics to Cover Identifying Partners Who we are What do our partners share Exploring
More informationSuccessful Collaboration and Preparedness in Global Governance
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Successful Collaboration and Preparedness in Global Governance ISARIC meeting London,
More informationTowards a Sustainable Global Infrastructure for Medical Countermeasures
Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from
More informationGlobal Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme
Global Challenges of Pandemic and Avian Influenza 19 December 2006 Keiji Fukuda Global influenza Programme Summary of Current H5N1 Situation 1997 First known outbreak infecting humans 18 people hospitalized
More informationLinking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning
Linking Pandemic Influenza Preparedness with Bioterrorism Vaccination Planning APHA Annual Meeting San Francisco, California Lara Misegades, MS Director of Infectious Disease Policy November 18, 2003 Overview
More informationLesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease
URI CMB 190 Issues in Biotechnology Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease 1. The film Contagion: (A) entirely depicts a situation that could never possibly happen
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationPreparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do
Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Based on current data and information from the Centers for Disease Control (CDC) and the U.S. Department Health and Human Services
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationPANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES
PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES A Presentation to the Council of State Governments Health Policy Forum by Jeffrey Levi, Ph.D., Executive Director Trust for America s Health June 23, 2006
More informationAssociation of Public Health Laboratories
STATEMENT BY DR. Peter A. Shult ON BEHALF OF THE ASSOCIATION OF PUBLIC HEALTH LABORATORIES DIRECTOR OF THE COMMUNICABLE DISEASES DIVISION OF THE WISCONSIN STATE LABORATORY OF HYGIENE ON Beyond the Checklist:
More informationAcute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).
Influenza glossary Adapted from the Centers for Disease Control and Prevention, US https://www.cdc.gov/flu/glossary/index.htm and the World Health Organization http://www.wpro.who.int/emerging_diseases/glossary_rev_sept28.pdf?ua=1
More informationBoehringer Ingelheim Biopharmaceuticals in China. Your Reliable Contract Manufacturing Solution Provider
Boehringer Ingelheim Biopharmaceuticals in China Your Reliable Contract Manufacturing Solution Provider Dr. Bin Wang, Dr. Axel Schleyer Boehringer Ingelheim Biopharmaceuticals (China) Co., Ltd. Contact:
More informationH1N1 Flu Virus Sudbury & District Health Unit Response. Shelley Westhaver May 2009
H1N1 Flu Virus Sudbury & District Health Unit Response Shelley Westhaver May 2009 Pandemic Influenza A global outbreak of disease that occurs when a new influenza virus appears or emerges in the human
More informationH1N1 influenza pandemic ( Spanish flu ) probably killed million people globally. Seasonal flu can cause ,000 deaths (WHO).
Influenza-1918-2018. Are we ready for another pandemic? 1918-20 H1N1 influenza pandemic ( Spanish flu ) probably killed 50-100 million people globally. Seasonal flu can cause 250-500,000 deaths (WHO).
More informationMemo. To: Pandemic Planning Partners. Subject: Pandemic Countermeasures Planning. Date:
Memo To: Pandemic Planning Partners Subject: Pandemic Countermeasures Planning Date: 2-27-08 The intent of this document is to assist local jurisdictions in planning for the receipt and use of pandemic
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationRoles and Responsibilities
Prior to the declaration of a public health emergency, State and local planners should examine existing State public health and medical licensing laws, interstate emergency management compacts and mutual
More informationCapturing lightning In A Bottle
Capturing lightning In A Bottle Featured In: Manufacturing & Capabilities I Facility of the Year I ISPE By Stephen Hall, Senior Director, Engineering, MannKind Corporation; Juergen Martens, Chief Technical
More informationAvian influenza Avian influenza ("bird flu") and the significance of its transmission to humans
15 January 2004 Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans The disease in birds: impact and control measures Avian influenza is an infectious disease
More informationPublic Safety and Health Cooperation from the Canadian Perspective
1 2 Public Safety and Health Cooperation from the Canadian Perspective Presentation by: Dr. Rainer Engelhardt Assistant Deputy Minister Infectious Disease Prevention and Control Public Health Agency of
More informationPandemic Influenza Preparedness & Response. Presented by the Cupertino Office of Emergency Services January 30, Start Video
Pandemic Influenza Preparedness & Response Presented by the Cupertino Office of Emergency Services January 30, 2008 Start Video Why the Concern About Pandemic Influenza? Influenza pandemics are inevitable;
More informationPANDEMIC INFLUENZA PLAN
PANDEMIC INFLUENZA PLAN August 13, 2009 Credits: We wish to acknowledge and thank Saskatoon Public Schools for their willingness to share information which served as the basis for this document. 1 Pandemic
More informationINFLUENZA PANDEMIC CONTINUED FOCUS ON THE NATION S PLANNING AND PREPAREDNESS EFFORTS REMAINS ESSENTIAL
INFLUENZA PANDEMIC CONTINUED FOCUS ON THE NATION S PLANNING AND PREPAREDNESS EFFORTS REMAINS ESSENTIAL page 1 / 5 page 2 / 5 influenza pandemic continued focus pdf The 2009 flu pandemic or swine flu was
More informationBARDA INDUSTRY DAYS 10 th Anniversary November 7-8, 2017
BARDA INDUSTRY DAYS 10 th Anniversary November 7-8, 2017 Below is a summary of the BARDA Industry Days Conference in D.C. November 7-8, 2017. Each year this conference is organized by the Biomedical Advanced
More informationDevon Community Resilience. Influenza Pandemics. Richard Clarke Emergency Preparedness Manager Public Health England South West Centre
Devon Community Resilience Influenza Pandemics Richard Clarke Emergency Preparedness Manager Public Health England South West Centre What is a pandemic? 2 Devon Community Resilience - Influenza Pandemics
More informationH1N1 Vaccine Campaign What worked? California Department of Public Health Immunization Branch
H1N1 Vaccine Campaign What worked? Hurdles and Barriers Frayed pre-pandemic infrastructure for immunization Brief period to construct complex vaccine delivery systems based on readjusted assumptions Vaccine
More informationAppendix 3: Federal Government Agencies Involved in Immunization
Appendix 3: Federal Government Agencies Involved in Immunization Department of Health and Human Services (HHS) Secretary of Health and Human Services Directs all HHS activities. Office of the Assistant
More informationMedicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017
Medicago: transforming the approach to vaccines and protein-based therapeutics Bruce D. Clark PhD President & CEO September 27, 2017 Medicago Overview Focus Manufacturing technology Vaccine technology
More informationASCO Power Control Systems Overview
ASCO Power Control Systems Overview POWER CONTROL CHALLENGES Today more than ever, continuous electrical power is essential for providing mission-critical services. Whether it s a hospital providing critical
More informationEmerging Infectious Disease Threats. Margaret A. Hamburg M.D. Foreign Secretary, U.S. National Academy of Medicine
Emerging Infectious Disease Threats Margaret A. Hamburg M.D. Foreign Secretary, U.S. National Academy of Medicine Plagues and History Leading causes of global deaths from infectious diseases Infectious
More information2009-H1N1 Pandemic Influenza: DHS Perspective
2009-H1N1 Pandemic Influenza: DHS Perspective Terry Adirim, MD, MPH Senior Advisor for Science and Public Health Office of Health Affairs U.S. Department of Homeland Security The National Emergency Management
More informationPREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day
PREventing EMerging Pathogenic Threats (PREEMPT) Proposers Day Dr. Jim Gimlett, Program Manager DARPA Biological Technologies Office (BTO) January 30, 2018 Arlington, VA PREEMPT Agenda Proposers Day Objectives
More informationAnnex H - Pandemic or Disease Outbreak
or Disease Outbreak Version: 1.0 Effective: 10/01/2015 Revision Date: 10/01/2015 Approved By: John Pitcher Purpose A pandemic is a worldwide epidemic of an infectious disease. It occurs when a new organism
More informationEmerging of the first NOVEL CANADIAN ADJUVANT and its potential in vaccine development and immunotherapy
Safe & Efficacious Adjuvanted Vaccines Platform Emerging of the first NOVEL CANADIAN ADJUVANT and its potential in vaccine development and immunotherapy Outline Science n Manufacture and Structure of PAL
More informationRequest for Letters of Intent. International Development of H5N1 Influenza Vaccines
Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop
More informationPandemic Influenza Preparedness
Pandemic Influenza Preparedness Of the many health threats that we are preparing for, this is the one that we know will happen. Bruce G. Gellin, MD, MPH Director, National Vaccine Program Office Department
More informationAssessment of Influenza Vaccine Production Compatibilities
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationUniversity of Prince Edward Island PANDEMIC PREPAREDNESS PLAN. October 7, 2009
University of Prince Edward Island PANDEMIC PREPAREDNESS PLAN October 7, 2009 University of Prince Edward Island PANDEMIC PREPAREDNESS PLAN Table of Contents Page 1.0 Introduction 3-6 1.1 Objective 1.2
More informationGlobal Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today
Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural
More informationPANDEMIC INFLUENZA: CURRENT THREAT AND CALL FOR ACTION. Kirsty Duncan PhD FSAScot
PANDEMIC INFLUENZA: CURRENT THREAT AND CALL FOR ACTION Kirsty Duncan PhD FSAScot NEW INFLUENZA VIRUS, NEW THREAT NEW STRAIN OF FLU COULD KILL MILLIONS AROUND THE WORLD WORLD IS NOT READY FOR A FLU PANDEMIC
More informationPlant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing
Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Nathalie Charland, PhD GHSI Workshop on Public Health Emergency Medical Countermeasures
More informationSMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE
SMARTPILOT FOR YPSOMATE: TRANSFORMING A PROVEN AUTOINJECTOR INTO A FULLY CONNECTED DEVICE In this article, Orfeo Niedermann, Business Development Director, Ypsomed Delivery Systems, provides insights into
More informationUSG Policy Perspectives on Global Influenza
USG Policy Perspectives on Global Influenza IOM Committee for the Assessment of DoD-GEIS Influenza Surveillance & Response Programs Ms. Ellen P. Embrey Deputy Assistant Secretary of Defense Force Health
More informationNow Is the Time To Prepare.
Now Is the Time To Prepare. If a natural disaster shuts down your local electricity service, could you keep your manufacturing lines running? How about the interior lights, phone lines and cash registers
More informationPandemic Influenza Cross Sectoral Preparedness and Planning
Opening statement Seminar on Pandemic Influenza Cross Sectoral Preparedness and Planning Ministry of Health and Care Services, Oslo 19. February 2009 State secretary Rigmor Aasrud Dear speakers, dear participants,
More informationBusiness Continuity and Crisis Management. Cardinal Health s Approach
Business Continuity and Crisis Management Cardinal Health s Approach Welcome We don t have ALL the answers Opportunity to share ideas Discussion around how we can work together to help prepare our communities,
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More informationInfluenza: The past, the present, the (future) pandemic
Influenza: The past, the present, the (future) pandemic Kristin Butler, MLS (ASCP) cm Department of Clinical Laboratory Sciences Louisiana Health Sciences Center - Shreveport Fall 2017 Objectives 1) Detail
More informationPlumas County Public Health Agency. Preparing the Community for Public Health Emergencies
Plumas County Public Health Agency Preparing the Community for Public Health Emergencies Business Continuity Planning For Family Medicine Practices Much of emergency planning is universal Cross-over benefit:
More informationGOVERNMENT OF ALBERTA. Alberta s Plan for Pandemic Influenza
GOVERNMENT OF ALBERTA Alberta s Plan for Pandemic Influenza November 2003 What is pandemic influenza? The word pandemic is used to describe diseases that cause worldwide outbreaks of illness involving
More informationEconomics of Vaccine Development A Vaccine Manufacturer s Perspective
Economics of Vaccine Development A Vaccine Manufacturer s Perspective Gerald Voss The Value of Vaccines 2 29 diseases are currently preventable by vaccination Global public health Cervical cancer 1 Diphtheria
More informationBARDA INFLUENZA PROGRAM OVERVIEW
BARDA INFLUENZA PROGRAM OVERVIEW Drs. Armen Donabedian and Michael Wathen Vaccines and Therapeutics Resilient People. Healthy Communities. A Nation Prepared. 0 BARDA Overview 1 Perpetual challenge of responding
More informationBoehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence
Boehringer Ingelheim BioXcellence Producing Value Global Contract Manufacturing Excellence Your World Class Contract Manufacturer Boehringer Ingelheim BioXcellence Producing Value Boehringer Ingelheim
More informationBefore and during influenza pandemics
before and during influenza pandemics Klaus Stöhr Department for Communicable Diseases Surveillance and Response Before and during influenza pandemics Before pandemics: interpandemic period New human influenza
More informationHumanitarian Logistics & Pandemic Influenza
Humanitarian Logistics & Pandemic Influenza Alastair Cook Budapest 22 nd October, 2009 Pandemic Influenza Influenza pandemics are naturally occurring events Influenza pandemics occur 2 3 times each century
More informationRe: Trust for America s Health Comments on Biennial Implementation Plan for the National Health Security Strategy
Dr. Nicole Lurie, MD, MSPH Assistant Secretary for Preparedness & Response Department of Health and Human Services Washington, DC 20201 Re: Trust for America s Health Comments on Biennial Implementation
More informationPandemic Influenza Preparedness and Response
Pandemic Influenza Preparedness and Response US Department of Health and Human Services Bruce Gellin, MD, MPH Director, National Vaccine Program Office The pandemic influenza clock is ticking. We just
More informationPandemic Influenza Preparedness Subpanel
Defense Health Board Pandemic Influenza Preparedness Subpanel Gregory A. Poland, MD Vice-President, Defense Health Board Chair, Select Subcommittee on PI Planning and Response Purpose Brief Background
More informationWhat Antivirals Can Be Used for 2009 H1N1 Influenza?
www.upmc-biosecurity.org www.upmc-cbn.org May 13, 2009 The Use of Antivirals for 2009 H1N1 Influenza Virus Infection By Ann Norwood, MD, Brooke Courtney, JD, MPH, Eric Toner, MD, and Amesh Adalja, MD Use
More informationCounty-Wide Pandemic Influenza Preparedness & Response Plan
County-Wide Pandemic Influenza Preparedness & Response Plan Presented by the Santa Clara County Public Health Department to the Emergency Managers Association April 27, 2006 Why the Concern About Pandemic
More informationPandemic Influenza: Considerations for Business Continuity Planning
Pandemic Influenza: Considerations for Business Continuity Planning Maine Telecommunications Users Group (MTUG) VTEC, South Portland, ME 10 October 2006 Steven J. Trockman, MPH Joshua C. Frances, NREMT-I
More informationPlanning for Pandemic Influenza
Planning for Pandemic Influenza John Kobayashi Faculty, Northwest Center for Public Health Practice, Foreign Advisor with the Field Epidemiology Training Program in Japan Pandemic Influenza as a Paradigm
More information100 Years since the 1918 Spanish Flu Pandemic. Current Standards for Flu Pandemic Preparedness
100 Years since the 1918 Spanish Flu Pandemic. Current Standards for Flu Pandemic Preparedness OCTOBER 16, 2018 SALLY A. HOJVAT M.Sc., Ph.D. Retired as Director of FDA Division of Microbiology Devices,
More informationLocal Government Pandemic Influenza Planning. Mac McClendon, Chief / Office of Public Health Preparedness Emergency Management Coordinator
Local Government Pandemic Influenza Planning Mac McClendon, Chief / Office of Public Health Preparedness Emergency Management Coordinator Harris County Public Health & Environmental Service Veterinarian
More informationOn behalf of the Infectious Diseases Society of America (IDSA), I am pleased to provide
Transmitted by Jonathan Nurse, Director of Government Relations, IDSA The Infectious Diseases Society of America s (IDSA) Fiscal Year 2015 Funding Statement Submitted to the House Appropriations Subcommittee
More informationSolutions for Unified Critical Communications. Influenza and Pandemic Preparedness: An Expert Panel Discussion
Solutions for Unified Critical Communications Influenza and Pandemic Preparedness: An Expert Panel Discussion Agenda Logistics Panel Introductions Introduction to Everbridge Panel Discussion Audience Q&A
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information Name of Manufacturer Prequalification Team WHO PUBLIC INSPECTION
More informationTHE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability
THE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability International Federation of Pharmaceutical Manufacturers & Associations THE COMPLEX JOURNEY
More informationRecommendations for Personal Protective Equipment Use During an Avian Influenza Pandemic
Recommendations for Personal Protective Equipment Use During an Avian Influenza Pandemic Prepared by Dennis K. Sullivan, BA, CEM, CHMM, EMT-P Assistant Director Department of Environmental Health and Safety
More information1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination
1918 Influenza; Influenza A, H1N1 Basic agent information Section I- Infectious Agent Risk Group: - RG3 Synonym or Cross reference: - Spanish Flu - 1918 Flu - El Grippe Characteristics: - SELECT AGENT
More informationWORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network
WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network Tokyo, July 2009 World Bank Response to A(H1N1) Influenza A(H1N1) Global Health and Risks
More informationPandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice
SUPPLEMENT ARTICLE Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice Julie L. Gerberding Centers for Disease Control and Prevention, Atlanta, Georgia Influenza pandemic
More informationFeasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China. Gu Hong Ministry of Agriculture of P. R. China
Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China Gu Hong Ministry of Agriculture of P. R. China AI -- common challenge to the all countries Global cooperation in control
More informationFinal Report for the Outbreak of Highly Pathogenic Avian Influenza (HPAI) in the United States
Final Report for the 2014 2015 Outbreak of Highly Pathogenic Avian Influenza (HPAI) in the United States USDA Animal and Plant Health Inspection Service Veterinary Services 1 Nature of Disease Avian influenza
More informationCDC Prepares Special Issue August 2006
CDC Prepares Special Issue August 2006 Fast Facts CDC s Influenza Pandemic Operation Plan The final draft of CDC s Influenza Pandemic Operation Plan has been completed and includes more than 1600 specific
More informationSecond intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network
Summary report on the Second intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network WHO-EM/CSR/070/E Sharm el-sheikh, Egypt 24 27 November 2013 Summary
More information